Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review.

Amy J C Dohmen, Justin E Swartz, Michiel W M Van Den Brekel, Stefan M Willems, René Spijker, Jacques Neefjes, Charlotte L Zuur
Author Information
  1. Amy J C Dohmen: Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands. a.dohmen@nki.nl.
  2. Justin E Swartz: Department of Otorhinolaryngology-Head and Neck Surgery, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3508 GA, The Netherlands. j.e.swartz@umcutrecht.nl.
  3. Michiel W M Van Den Brekel: Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands. m.vd.brekel@nki.nl.
  4. Stefan M Willems: Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3508 GA, The Netherlands. s.m.willems-4@umcutrecht.nl.
  5. René Spijker: Medical library, Academic Medical Center, Amsterdam 1100 DE, The Netherlands. r.spijker@amc.uva.nl.
  6. Jacques Neefjes: Department of Cell Biology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands. j.neefjes@nki.nl.
  7. Charlotte L Zuur: Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands. c.zuur@nki.nl.

Abstract

Primary human tumor culture models allow for individualized drug sensitivity testing and are therefore a promising technique to achieve personalized treatment for cancer patients. This would especially be of interest for patients with advanced stage head and neck cancer. They are extensively treated with surgery, usually in combination with high-dose cisplatin chemoradiation. However, adding cisplatin to radiotherapy is associated with an increase in severe acute toxicity, while conferring only a minor overall survival benefit. Hence, there is a strong need for a preclinical model to identify patients that will respond to the intended treatment regimen and to test novel drugs. One of such models is the technique of culturing primary human tumor tissue. This review discusses the feasibility and success rate of existing primary head and neck tumor culturing techniques and their corresponding chemo- and radiosensitivity assays. A comprehensive literature search was performed and success factors for culturing in vitro are debated, together with the actual value of these models as preclinical prediction assay for individual patients. With this review, we aim to fill a gap in the understanding of primary culture models from head and neck tumors, with potential importance for other tumor types as well.

Keywords

References

  1. Cancer. 1984 Apr 15;53(8):1736-40 [PMID: 6697312]
  2. Cancer Res. 2005 Feb 15;65(4):1271-6 [PMID: 15735012]
  3. Cancer Res. 1981 Nov;41(11 Pt 1):4378-81 [PMID: 7306965]
  4. Surg Today. 2002;32(6):477-81 [PMID: 12107769]
  5. Int J Cancer. 2016 Jan 1;138(1):171-81 [PMID: 26178914]
  6. Cancer Res. 1981 May;41(5):1657-63 [PMID: 7214336]
  7. Chem Rev. 2013 May 8;113(5):3214-47 [PMID: 23425060]
  8. Int J Cancer. 2004 Jul 10;110(5):701-9 [PMID: 15146560]
  9. Cancer Res. 1988 May 1;48(9):2432-9 [PMID: 3356007]
  10. Br J Cancer. 1978 Feb;37(2):261-8 [PMID: 343804]
  11. Scand J Immunol. 2008 Apr;67(4):392-9 [PMID: 18282234]
  12. Br J Cancer. 1999 Mar;79(7-8):1074-84 [PMID: 10098739]
  13. Int J Cancer. 1992 Apr 22;51(1):99-107 [PMID: 1563848]
  14. Cancer. 1984 Jan 15;53(2):286-90 [PMID: 6360338]
  15. Laryngoscope. 1982 Jul;92(7 Pt 2 Suppl 28):1-26 [PMID: 7087657]
  16. Scand J Immunol. 2000 Mar;51(3):271-8 [PMID: 10736096]
  17. Cytometry. 1985 Jul;6(4):334-41 [PMID: 2990834]
  18. In Vitro. 1983 Aug;19(8):600-10 [PMID: 6885100]
  19. Clin Cancer Res. 1995 Mar;1(3):305-11 [PMID: 9815986]
  20. Arch Otolaryngol. 1980 Nov;106(11):672-4 [PMID: 7425937]
  21. Br J Cancer. 2014 Jan 21;110(2):479-88 [PMID: 24263061]
  22. Ann Biomed Eng. 2012 Jun;40(6):1277-88 [PMID: 21997391]
  23. Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):3-7 [PMID: 8416879]
  24. J Clin Oncol. 2013 Mar 1;31(7):845-52 [PMID: 23182993]
  25. J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [PMID: 18270337]
  26. Anticancer Res. 2006 Mar-Apr;26(2B):1651-5 [PMID: 16619587]
  27. Oral Oncol. 2007 Sep;43(8):749-56 [PMID: 17112769]
  28. Anticancer Res. 2001 May-Jun;21(3B):1953-63 [PMID: 11497283]
  29. Oncology. 2013;85(5):290-6 [PMID: 24217231]
  30. Anticancer Res. 2004 Sep-Oct;24(5A):2947-51 [PMID: 15517901]
  31. Cancer Res. 1993 May 1;53(9):2140-6 [PMID: 8481917]
  32. Int J Radiat Biol. 1989 Nov;56(5):751-60 [PMID: 2573673]
  33. Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):849-53 [PMID: 9369133]
  34. Anticancer Res. 2004 Jan-Feb;24(1):325-31 [PMID: 15015616]
  35. Anticancer Res. 2013 Mar;33(3):1029-34 [PMID: 23482777]
  36. Radiother Oncol. 2009 Jul;92(1):4-14 [PMID: 19446902]
  37. Int J Cancer. 2015 Jun 15;136(12 ):2775-85 [PMID: 25388642]
  38. J Cell Physiol Suppl. 1984;3:105-16 [PMID: 6589227]
  39. Am J Surg. 1980 Oct;140(4):527-30 [PMID: 7425237]
  40. J Natl Cancer Inst. 1990 Jan 17;82(2):96-101 [PMID: 2403594]
  41. Head Neck. 2002 May;24(5):437-42 [PMID: 12001073]
  42. Cancer Metastasis Rev. 1996 Mar;15(1):27-51 [PMID: 8842478]
  43. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3294-8 [PMID: 8475071]
  44. Clin Cancer Res. 1995 Dec;1(12):1537-43 [PMID: 9815954]
  45. Stem Cells Transl Med. 2014 Sep;3(9):1055-65 [PMID: 25024430]
  46. Cancer Immunol Immunother. 1995 May;40(5):283-91 [PMID: 7600559]
  47. Cancer Metastasis Rev. 1985;4(2):107-24 [PMID: 2990670]
  48. Acta Otolaryngol. 2005 Oct;125(10):1097-104 [PMID: 16298793]
  49. Laryngoscope. 1994 Mar;104(3 Pt 1):335-40 [PMID: 8127192]
  50. J Natl Cancer Inst. 1951 Dec;12(3):545-61 [PMID: 14889259]
  51. J Exp Med. 1956 Feb 1;103(2):273-83 [PMID: 13286432]
  52. Cancer Chemother Pharmacol. 2010 May;65(6):1153-63 [PMID: 19771432]
  53. Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1283-6 [PMID: 2370177]
  54. Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):13-9 [PMID: 10656366]
  55. Acta Otolaryngol. 1987 May-Jun;103(5-6):529-36 [PMID: 2441566]
  56. J Clin Lab Anal. 1991;5(2):133-43 [PMID: 2023059]
  57. Arch Otolaryngol Head Neck Surg. 1994 Mar;120(3):288-92 [PMID: 8123238]
  58. Acta Otolaryngol. 1997 Sep;117(5):775-84 [PMID: 9349880]
  59. Laryngoscope. 1989 Dec;99(12):1255-61 [PMID: 2601539]
  60. Radiother Oncol. 1995 Nov;37(2):87-99 [PMID: 8747932]
  61. Cancer Res. 1987 Jan 1;47(1):106-10 [PMID: 3791195]
  62. J Surg Oncol. 1980;13(1):9-20 [PMID: 6243380]
  63. Head Neck. 2016 Apr;38 Suppl 1:E911-5 [PMID: 25994489]
  64. Anticancer Res. 1997 Sep-Oct;17(5A):3225-31 [PMID: 9413152]
  65. Life Sci. 1992;50(22):1711-8 [PMID: 1588802]
  66. Semin Oncol. 1989 Apr;16(2):91-105 [PMID: 2652316]
  67. Oral Oncol. 2001 Jun;37(4):386-92 [PMID: 11337272]
  68. Mol Pathol. 1999 Feb;52(1):42-6 [PMID: 10439839]
  69. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):676-81 [PMID: 18355979]
  70. Indian J Cancer. 2007 Oct-Dec;44(4):142-6 [PMID: 18322356]
  71. Exp Cell Res. 2012 Jun 10;318(10):1104-11 [PMID: 22426199]
  72. Am J Pathol. 1984 Jun;115(3):397-402 [PMID: 6375391]
  73. Br J Cancer. 2002 Jul 15;87(2):202-7 [PMID: 12107843]
  74. Cancer Res. 2014 Dec 15;74(24):7546-59 [PMID: 25320014]
  75. Oral Oncol. 2011 Feb;47(2):83-91 [PMID: 21167769]
  76. Br J Cancer. 1981 Jun;43(6):772-85 [PMID: 7195729]
  77. Scand J Immunol. 2001 Feb;53(2):162-70 [PMID: 11169220]
  78. Cell Physiol Biochem. 2015;36(2):784-98 [PMID: 26021266]
  79. Anticancer Res. 1991 Jan-Feb;11(1):273-9 [PMID: 2018361]
  80. J Clin Oncol. 2003 Jan 1;21(1):92-8 [PMID: 12506176]
  81. Head Neck. 2016 Apr;38 Suppl 1:E459-67 [PMID: 25677579]
  82. Eur J Cancer. 1997 Mar;33(3):453-62 [PMID: 9155532]
  83. Anticancer Res. 2015 Jul;35(7):3917-24 [PMID: 26124338]
  84. Proc Natl Acad Sci U S A. 1955 Jul 15;41(7):432-7 [PMID: 16589695]
  85. Radiother Oncol. 1999 Jan;50(1):47-55 [PMID: 10225557]
  86. Am J Pathol. 1993 Feb;142(2):413-23 [PMID: 8382008]
  87. Science. 1977 Jul 29;197(4302):461-3 [PMID: 560061]
  88. Anticancer Res. 2006 May-Jun;26(3B):2361-5 [PMID: 16821617]
  89. Cancer. 1991 Jun 1;67(11):2741-7 [PMID: 2025837]
  90. Oral Oncol. 2003 Oct;39(7):701-7 [PMID: 12907210]
  91. Int J Gynecol Cancer. 2005 May-Jun;15(3):445-52 [PMID: 15882168]
  92. J Chemother. 1989 Feb;1(1):59-63 [PMID: 2723714]
  93. N Engl J Med. 1957 Dec 19;257(25):1207-11 [PMID: 13493708]
  94. Cancer Res. 1986 Mar;46(3):1263-74 [PMID: 3484678]
  95. Head Neck. 2007 Feb;29(2):163-88 [PMID: 17312569]
  96. Br J Cancer. 1998 Jun;77(12):2371-5 [PMID: 9649161]
  97. Cancer Control. 2002 Sep-Oct;9(5):387-99 [PMID: 12410178]
  98. Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):789-94 [PMID: 7960980]
  99. Virology. 1964 Jun;23:291-4 [PMID: 14187925]
  100. Oncologist. 2010;15(9):994-1001 [PMID: 20798198]
  101. Cancer Res. 1985 Sep;45(9):4200-5 [PMID: 4028010]
  102. Anticancer Res. 2000 May-Jun;20(3B):2049-54 [PMID: 10928150]
  103. Anticancer Res. 1989 Jul-Aug;9(4):1089-94 [PMID: 2479326]
  104. Oral Oncol. 2003 Jul;39(5):515-20 [PMID: 12747977]
  105. N Engl J Med. 1983 Jan 20;308(3):154-5 [PMID: 6336821]
  106. Otolaryngol Head Neck Surg. 2014 Jan;150(1):73-80 [PMID: 24098006]
  107. Radiother Oncol. 1994 Sep;32(3):218-25 [PMID: 7529415]
  108. Ann Otol Rhinol Laryngol. 2014 Sep;123(9):662-72 [PMID: 24816422]

Word Cloud

Created with Highcharts 10.0.0tumormodelspatientsheadneckprimarycancerculturingPrimaryhumanculturetechniquepersonalizedtreatmentcisplatinpreclinicalreviewsuccessradiosensitivityallowindividualizeddrugsensitivitytestingthereforepromisingachieveespeciallyinterestadvancedstageextensivelytreatedsurgeryusuallycombinationhigh-dosechemoradiationHoweveraddingradiotherapyassociatedincreasesevereacutetoxicityconferringminoroverallsurvivalbenefitHencestrongneedmodelidentifywillrespondintendedregimentestnoveldrugsOnetissuediscussesfeasibilityrateexistingtechniquescorrespondingchemo-assayscomprehensiveliteraturesearchperformedfactorsvitrodebatedtogetheractualvaluepredictionassayindividualaimfillgapunderstandingtumorspotentialimportancetypeswellFeasibilityTumorCultureModelsPreclinicalPredictionAssaysHeadNeckCancer:NarrativeReviewchemosensitivitytherapycellcultures

Similar Articles

Cited By